This groundbreaking development may enable treatments for inflammatory diseases such as Crohn's and colitis.Researchers at ...

The family of Andy McKnight have announced details of his funeral following his death last September. Our thoughts are with ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

Diversify Wealth Management LLC lifted its holdings in shares of Option Care Health, Inc. (NASDAQ:OPCH – Free Report) by 31.7 ...

I used to be you!” I wanted to cry out. “Do a self-breast check!” Just one year before, I often wore that very same “HEALTH!” shirt, back when I thought health was something you could buy and show off ...

The findings suggest that lipid composition can direct mRNA-based drugs to target organs, such as the intestines, without passing through the liver.

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO NANTES, France - ...

July 17, 2023 — Chronic inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, is on the rise worldwide. The benefits of current medications are limited by problematic ...

French biotech moves on with the late stage drug development, after publishing impressive clinical trial results of ABX464 for treatment of colitis and hinting its potential in Crohn’s disease.

Crohn's disease and ulcerative colitis are idiopathic, chronic, relapsing, inflammatory conditions that are immunologically mediated. Although their exact etiologies remain uncertain, results from ...